Tatsis Ourania's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Jun 3, 2024
- Accession no.
- 0000875320-24-000166
- Filed
- Jun 3, 2024
- Trade date
- May 30-31, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $2.03M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tatsis OuraniaCIK 0001789815 | Officer (EVP, Chief Reg. & Quality Off.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 30, 2024 | Common Stock | SSaleDisposed | −2,350 | $439.11 | −$1,031,908.5 | 53,523 | Direct | |
| May 31, 2024 | Common Stock | SSaleDisposed | −2,250 | $445.00 | −$1,001,250 | 51,273 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.